549 related articles for article (PubMed ID: 25975662)
21. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
22. α-Tocopherol is an effective Phase II enzyme inducer: protective effects on acrolein-induced oxidative stress and mitochondrial dysfunction in human retinal pigment epithelial cells.
Feng Z; Liu Z; Li X; Jia H; Sun L; Tian C; Jia L; Liu J
J Nutr Biochem; 2010 Dec; 21(12):1222-31. PubMed ID: 20153624
[TBL] [Abstract][Full Text] [Related]
23. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
24. Differences in Uptake and Intracellular Fate between Bevacizumab and Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment Epithelium.
Borchers L; Roider J; Klettner A
Ophthalmic Res; 2021; 64(3):369-388. PubMed ID: 33011724
[TBL] [Abstract][Full Text] [Related]
25. Compatibility of recombinant tissue plasminogen activator (rtPA) and aflibercept or ranibizumab coapplied for neovascular age-related macular degeneration with submacular haemorrhage.
Klettner A; Grotelüschen S; Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2015 Jun; 99(6):864-9. PubMed ID: 25740806
[TBL] [Abstract][Full Text] [Related]
26. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione.
Miura Y; Klettner A; Roider J
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4848-55. PubMed ID: 20435596
[TBL] [Abstract][Full Text] [Related]
27. p38 mitogen-activated protein kinase protects human retinal pigment epithelial cells exposed to oxidative stress.
Pocrnich CE; Liu H; Feng M; Peng T; Feng Q; Hutnik CM
Can J Ophthalmol; 2009 Aug; 44(4):431-6. PubMed ID: 19606165
[TBL] [Abstract][Full Text] [Related]
28. Effects of Bevacizumab on Bcl-2 Expression and Apoptosis in Retinal Pigment Epithelial Cells under Oxidative Stress.
Kim S; Kim YJ; Kim NR; Chin HS
Korean J Ophthalmol; 2015 Dec; 29(6):424-32. PubMed ID: 26635460
[TBL] [Abstract][Full Text] [Related]
29. Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.
Shen W; Yau B; Lee SR; Zhu L; Yam M; Gillies MC
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28257068
[TBL] [Abstract][Full Text] [Related]
30. Hydroxytyrosol protects retinal pigment epithelial cells from acrolein-induced oxidative stress and mitochondrial dysfunction.
Liu Z; Sun L; Zhu L; Jia X; Li X; Jia H; Wang Y; Weber P; Long J; Liu J
J Neurochem; 2007 Dec; 103(6):2690-700. PubMed ID: 20938484
[TBL] [Abstract][Full Text] [Related]
31. Effects of aflibercept on primary RPE cells: toxicity, wound healing, uptake and phagocytosis.
Klettner A; Tahmaz N; Dithmer M; Richert E; Roider J
Br J Ophthalmol; 2014 Oct; 98(10):1448-52. PubMed ID: 25034050
[TBL] [Abstract][Full Text] [Related]
32. The matricellular protein CCN5 prevents anti-VEGF drug-induced epithelial-mesenchymal transition of retinal pigment epithelium.
Im S; Song MH; Elangovan M; Woo KM; Park WJ
Sci Rep; 2024 Jun; 14(1):13920. PubMed ID: 38886213
[TBL] [Abstract][Full Text] [Related]
33. Effect of Long-term Anti-VEGF Treatment on Viability and Function of RPE Cells.
Brinkmann A; Winkelmann K; Käckenmeister T; Roider J; Klettner A
Curr Eye Res; 2022 Jan; 47(1):127-134. PubMed ID: 33998943
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab and Aflibercept Activate Platelets via FcγRIIa.
Nomura Y; Kaneko M; Miyata K; Yatomi Y; Yanagi Y
Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8075-82. PubMed ID: 26720459
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
Pfau M; Fassnacht-Riederle H; Becker MD; Graf N; Michels S
Ophthalmic Res; 2015; 54(3):150-6. PubMed ID: 26413794
[TBL] [Abstract][Full Text] [Related]
36. Bevacizumab modulates epithelial-to-mesenchymal transition in the retinal pigment epithelial cells via connective tissue growth factor up-regulation.
Chen CL; Liang CM; Chen YH; Tai MC; Lu DW; Chen JT
Acta Ophthalmol; 2012 Aug; 90(5):e389-98. PubMed ID: 22712616
[TBL] [Abstract][Full Text] [Related]
37. Curcumin analog 1, 5-bis (2-trifluoromethylphenyl)-1, 4-pentadien-3-one exhibits enhanced ability on Nrf2 activation and protection against acrolein-induced ARPE-19 cell toxicity.
Li Y; Zou X; Cao K; Xu J; Yue T; Dai F; Zhou B; Lu W; Feng Z; Liu J
Toxicol Appl Pharmacol; 2013 Nov; 272(3):726-35. PubMed ID: 23954767
[TBL] [Abstract][Full Text] [Related]
38. 3,3'-Diindolylmethane inhibits VEGF expression through the HIF-1α and NF-κB pathways in human retinal pigment epithelial cells under chemical hypoxic conditions.
Park H; Lee DS; Yim MJ; Choi YH; Park S; Seo SK; Choi JS; Jang WH; Yea SS; Park WS; Lee CM; Jung WK; Choi IW
Int J Mol Med; 2015 Jul; 36(1):301-8. PubMed ID: 25955241
[TBL] [Abstract][Full Text] [Related]
39. Response to anti-VEGF-A treatment of endothelial cells in vitro.
Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
Exp Eye Res; 2016 May; 146():128-136. PubMed ID: 26771090
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of canolol from oxidative stress-induced cell damage in ARPE-19 cells via an ERK mediated antioxidative pathway.
Dong X; Li Z; Wang W; Zhang W; Liu S; Zhang X; Fang J; Maeda H; Matsukura M
Mol Vis; 2011; 17():2040-8. PubMed ID: 21850179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
